News
KalVista Pharmaceuticals provides progress update on KVD 900 for oral on-demand treatment of hereditary angioedema.
KalVista Pharmaceuticals has provided an update on the clinical trial progress for KVD 900 in development for oral on-demand treatment of hereditary angioedema (HAE).
The company had a productive End-of-Phase II meeting with the FDA and recently received meeting minutes which confirmed that their Phase III trial design, similar to the recent Phase II trial, is expected to be appropriate to support an NDA submission. The development team is finalizing the Phase III trial protocol and preparing for study initiation, and anticipates patients will be dosed during the first quarter of 2022.
Condition: Hereditary Angio-Oedema
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.